Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients

scientific article published on 01 January 2003

Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1020093504
P356DOI10.1007/BF03256640
P698PubMed publication ID14720023

P2093author name stringJoan B Soriano
Jørgen Vestbo
Victor A Kiri
Neil B Pride
P433issue1
P921main subjectchronic obstructive pulmonary diseaseQ199804
P304page(s)67-74
P577publication date2003-01-01
P1433published inTreatments in Respiratory MedicineQ15755236
P1476titleInhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients
P478volume2

Reverse relations

cites work (P2860)
Q46476422A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination
Q37018812Changing the burden of COPD mortality
Q91624819Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Q37017520Comparison and optimal use of fixed combinations in the management of COPD.
Q43884681Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population
Q36135425Differences in COPD-related readmissions to primary and secondary care hospitals
Q52949846Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.
Q37785279Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease
Q36255228Effects of inhaled corticosteroids on mortality and hospitalisation in elderly asthma and chronic obstructive pulmonary disease patients: appraising the evidence
Q51599981Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.
Q34252132Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
Q37017524Genetic predisposition to accelerated decline of lung function in COPD
Q37532050Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.
Q34065276Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective
Q35871163Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease
Q36815073Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?
Q34691221Markers of exacerbation severity in chronic obstructive pulmonary disease
Q36742804Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena
Q35834324Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
Q37336771Optimising treatment for COPD--new strategies for combination therapy
Q36859405Optimizing economic outcomes in the management of COPD.
Q95264388Predicting and preventing hospital readmission for exacerbations of COPD
Q37018817Salmeterol/fluticasone combination in the treatment of COPD.
Q36993392Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease
Q36779343Tackling COPD: a multicomponent disease driven by inflammation
Q37748948The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
Q33966009The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.
Q60302185Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: Impact on mortality
Q80190969[Contribution of cohort studies on exacerbations and their management]

Search more.